MX2016016742A - Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). - Google Patents

Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).

Info

Publication number
MX2016016742A
MX2016016742A MX2016016742A MX2016016742A MX2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A
Authority
MX
Mexico
Prior art keywords
ceramide
group
complications
predicting
ceramides
Prior art date
Application number
MX2016016742A
Other languages
English (en)
Inventor
Laaksonen Reijo
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of MX2016016742A publication Critical patent/MX2016016742A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención proporciona, entre otras cosas, un método, y uso del mismo, para predecir complicaciones CV tales como IAM, SCA, accidente cerebrovascular y muerte CV determinando la concentración de por lo menos una ceramida del Grupo A y por lo menos una ceramida del Grupo B en una muestra biológica y comparando esas concentraciones con un control. Encontrar una concentración reducida de por lo menos una ceramida del Grupo A y una concentración elevada de por lo menos una ceramida del Grupo B indica que el sujeto tiene un mayor riesgo de desarrollar una o más complicaciones CV. También se proporciona un subconjunto recientemente identificado de moléculas de ceramida, versiones marcadas de las mismas, y kits y composiciones que comprenden las mismas para su uso en la predicción y/o el diagnóstico de complicaciones CV.
MX2016016742A 2014-06-16 2015-06-16 Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). MX2016016742A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462012543P 2014-06-16 2014-06-16
US14/677,595 US9347960B2 (en) 2014-06-16 2015-04-02 Ceramides and their use in diagnosing CVD
PCT/EP2015/063492 WO2015193325A2 (en) 2014-06-16 2015-06-16 Ceramides and their use in diagnosing cvd

Publications (1)

Publication Number Publication Date
MX2016016742A true MX2016016742A (es) 2017-04-27

Family

ID=54835950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016742A MX2016016742A (es) 2014-06-16 2015-06-16 Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).

Country Status (11)

Country Link
US (4) US9347960B2 (es)
EP (2) EP4089416A1 (es)
JP (1) JP6774879B2 (es)
KR (2) KR20240023696A (es)
CN (1) CN106461685B (es)
BR (1) BR112016028534A2 (es)
CA (1) CA2951578A1 (es)
MX (1) MX2016016742A (es)
SA (1) SA516380503B1 (es)
SG (1) SG11201609621RA (es)
WO (1) WO2015193325A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
US10996231B2 (en) * 2014-12-16 2021-05-04 Washington University Ceramides for evaluating risk of cardiovascular disease
EP3714273A1 (en) * 2017-11-20 2020-09-30 Zora Biosciences OY Methods for prediction and early detection of diabetes
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2020112149A1 (en) * 2018-12-01 2020-06-04 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for the assessment of acute myocardial infarction (ami)
EP3891509A1 (en) * 2018-12-06 2021-10-13 Zora Biosciences OY Biomarkers for cardiovascular events
CN112730638B (zh) * 2020-11-25 2022-07-29 首都医科大学附属北京朝阳医院 糖尿病合并心梗代谢标志物、检测试剂及试剂盒
CN112986454A (zh) * 2021-05-18 2021-06-18 天津云检医疗器械有限公司 急性心肌梗死的血清标志物、试剂盒和用途
CN113495160B (zh) * 2021-09-07 2021-11-19 宝枫生物科技（北京）有限公司 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用
WO2023108294A1 (en) * 2021-12-17 2023-06-22 National Research Council Of Canada Diagnostic lipid biomarkers for covid-19 and methods for use thereof
CN116500179B (zh) * 2023-04-21 2023-12-26 南京品生医疗科技有限公司 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012137A1 (en) 2010-01-29 2011-08-04 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
US9201080B2 (en) * 2010-06-20 2015-12-01 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP3190418B1 (en) 2011-07-28 2019-05-01 metanomics GmbH Use of sm_sphingomyelin (d18:1, c16:0) as a marker for heart failure
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2909626B1 (en) 2012-10-18 2018-07-04 metanomics GmbH Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample
JP2016511407A (ja) 2013-03-08 2016-04-14 ゾラ バイオサイエンシーズ オサケ ユキチュア 非高比重リポタンパク質由来ｃｖｄマーカー
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD

Also Published As

Publication number Publication date
EP4089416A1 (en) 2022-11-16
KR102636885B1 (ko) 2024-02-19
US10197582B2 (en) 2019-02-05
US20220163547A1 (en) 2022-05-26
KR20170018905A (ko) 2017-02-20
CN106461685B (zh) 2021-05-25
SA516380503B1 (ar) 2023-03-23
WO2015193325A3 (en) 2016-02-25
US11940453B2 (en) 2024-03-26
US9347960B2 (en) 2016-05-24
US11474116B2 (en) 2022-10-18
EP3155440A2 (en) 2017-04-19
CN106461685A (zh) 2017-02-22
KR20240023696A (ko) 2024-02-22
US20190113531A1 (en) 2019-04-18
WO2015193325A2 (en) 2015-12-23
JP6774879B2 (ja) 2020-10-28
BR112016028534A2 (pt) 2017-08-22
US20150362513A1 (en) 2015-12-17
JP2017519989A (ja) 2017-07-20
EP3155440B1 (en) 2022-04-20
CA2951578A1 (en) 2015-12-23
US20160266152A1 (en) 2016-09-15
SG11201609621RA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112017018821A2 (pt) métodos para quantificação de níveis de insulina através de espectrometria de massa
GB2556004A (en) Markers of stroke and stroke severity
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
MX2021009297A (es) Composiciones, dispositivos, y metodos de pruebas de sensibilidad del ibs.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
WO2017097852A3 (en) Use of ceramides and lpls in diagnosing cvd
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
GB2552271A (en) A method for diagnosing lung cancer
WO2014151290A3 (en) Assay for predictive biomarkers
MX2023006660A (es) Composiciones, dispositivos, y metodos de pruebas de sensibilidad a la osteoartritis.
EA201691168A1 (ru) Способы исследования бета-глюкана
SG10201907690TA (en) Device and method for detecting target molecules
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
MX2016015531A (es) Ensayo de inflamacion oral.
WO2015193552A3 (en) Means and methods for determining risk of type-1 diabetes by serum protein biomarkers